AXL in cancer: a modulator of drug resistance and therapeutic target

被引：34

作者：

Tang, Yaoxiang ^{[1
]}

Zang, Hongjing ^{[1
]}

Wen, Qiuyuan ^{[1
]}

Fan, Songqing ^{[1
]}

机构：

[1] Cent South Univ, Xiangya Hosp 2, Dept Pathol, Changsha 410011, Hunan, Peoples R China

来源：

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH | 2023年 / 42卷 / 01期

基金：

中国国家自然科学基金;

关键词：

AXL; Cancer; Drug resistance; Target therapy; Molecular mechanisms; RECEPTOR TYROSINE KINASE; EPITHELIAL-MESENCHYMAL TRANSITION; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; BREAST-CANCER; DNA-DAMAGE; GAS6/AXL AXIS; EGFR-TKI; INHIBITION; PROMOTES;

D O I：

10.1186/s13046-023-02726-w

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

AXL is a member of the TAM (TYRO3, AXL, and MERTK) receptor tyrosine kinases family (RTKs), and its abnormal expression has been linked to clinicopathological features and poor prognosis of cancer patients. There is mounting evidence supporting AXL's role in the occurrence and progression of cancer, as well as drug resistance and treatment tolerance. Recent studies revealed that reducing AXL expression can weaken cancer cells' drug resistance, indicating that AXL may be a promising target for anti-cancer drug treatment. This review aims to summarize the AXL's structure, the mechanisms regulating and activating it, and its expression pattern, especially in drug-resistant cancers. Additionally, we will discuss the diverse functions of AXL in mediating cancer drug resistance and the potential of AXL inhibitors in cancer treatment.

引用

页数：14

共 50 条

[31] Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy
Ye, Jing
Wu, Junhao
Liu, Bo
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2023, 1878 (03):
[32] Functions of methyltransferase-like 3 in breast cancer: pathogenesis, drug resistance, and therapeutic target
Xiao, Dongqiong
Zhang, Mingfu
Qu, Yi
Su, Xiaojuan
BREAST CANCER RESEARCH, 2024, 26 (01)
[33] CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer
Shanshan Gao
Fraser Soares
Shiyan Wang
Chi Chun Wong
Huarong Chen
Zhenjie Yang
Weixin Liu
Minnie Y. Y. Go
Musaddeque Ahmed
Yong Zeng
Catherine Adell O’Brien
Joseph J. Y. Sung
Housheng Hansen He
Jun Yu
Oncogene, 2021, 40 : 6601 - 6613
[34] The implications of ABCC3 in cancer drug resistance: can we use it as a therapeutic target?
Ramirez-Cosmes, Adriana
Reyes-Jimenez, Edilburga
Zertuche-Martinez, Cecilia
Hernandez-Hernandez, Carlos A.
Garcia-Roman, Rebeca
Romero-Diaz, Roberto, I
Manuel-Martinez, Adan E.
Elizarraras-Rivas, Jesus
Vasquez-Garzon, Veronica R.
AMERICAN JOURNAL OF CANCER RESEARCH, 2021, 11 (09): : 4127 - 4140
[35] CRISPR screens identify cholesterol biosynthesis as a therapeutic target on stemness and drug resistance of colon cancer
Gao, Shanshan
Soares, Fraser
Wang, Shiyan
Wong, Chi Chun
Chen, Huarong
Yang, Zhenjie
Liu, Weixin
Go, Minnie Y. Y.
Ahmed, Musaddeque
Zeng, Yong
O'Brien, Catherine Adell
Sung, Joseph J. Y.
He, Housheng Hansen
Yu, Jun
ONCOGENE, 2021, 40 (48) : 6601 - 6613
[36] Annexin A2: the feasibility of being a therapeutic target associated with cancer metastasis and drug resistance in cancer microenvironment
Weijie, Song
DISCOVER ONCOLOGY, 2024, 15 (01)
[37] Breast Cancer Resistance Protein: A Potential Therapeutic Target for Cancer
Mehendale-Munj, Sonali
Sawant, Shivangi
CURRENT DRUG TARGETS, 2021, 22 (04) : 409 - 417
[38] Drug resistance: the next target for cancer treatment
Hawkes, Nigel
BMJ-BRITISH MEDICAL JOURNAL, 2019, 365 : l2228
[39] Noncoding RNAs: an emerging modulator of drug resistance in pancreatic cancer
Wei, Ling
Sun, Jujie
Wang, Xingwu
Huang, Yizhou
Huang, Linying
Han, Linyu
Zheng, Yanxiu
Xu, Yuan
Zhang, Nasha
Yang, Ming
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2023, 11
[40] Therapeutic Nanoparticles to Combat Cancer Drug Resistance
Hu, Che-Ming Jack
Zhang, Liangfang
CURRENT DRUG METABOLISM, 2009, 10 (08) : 836 - 841

← 1 2 3 4 5 →